Downstream Process Optimization Opportunities Using On-Line and At-Line PAT Instrumentation - Technologies for downstream process applications continue to emerge as the PAT initiative is fully impleme


Downstream Process Optimization Opportunities Using On-Line and At-Line PAT Instrumentation
Technologies for downstream process applications continue to emerge as the PAT initiative is fully implemented into biotechnology manufacturing.

BioPharm International

Liquid chromatography has been successfully employed in pharmaceutical PAT applications for decades. Of particular note are the pioneering examples of on-line high performance liquid chromatography (HPLC) applications by Eli Lilly in biotechnology applications.7 On-line downstream applications of HPLC for biotechnology are now widely accepted and deployed. Commercial systems for biotech process monitoring are available from Dionex and other suppliers. This technique is mature, well characterized, and well accepted in all fields of chemistry separation including biotechnology. The system also requires capture of a physical sample from the process stream while maintaining sterility of the stream. Recent advances in on-line sampling for biotechnology, including introduction of commercial products that maintain process sterility, will further increase utilization of the HPLC technique in downstream applications.8 The chief drawback of this technique for process characterization appears to be the complexity of fully automated HPLC systems and their attendant control processes. These include column switching, fast column equilibration, and high flow systems, all of which are strategies employed to reduce cycle times to remain consistent with downstream needs.

Electrophoretic Techniques

Electrophoretic techniques, most notably slab gel electrophoresis for protein and genetics analysis, have been a mainstay of biotechnology development analytical laboratories since its commercial inception in the 1970s. Slab gel electrophoresis is simple in concept, inexpensive to acquire, does have high operating costs, and has cycle times inconsistent with the needs of downstream processing. Capillary electrophoresis (HPCE), was introduced in the late 1980s and automates the electrophoresis process in a format similar to HPLC. Many commercial instruments are available today. Data are quantitative in contrast to slab gel techniques. It is rapid. It has recently found widespread application for protein analysis in off line laboratories operated in support of downstream applications, specifically for protein product quality, characterization, and quantitation. The technique is inherently fast, versatile in the biotechnology environment, and amenable to the demands of protein assay in the downstream process environment. The technique is employed daily in this capacity, but still has failed to gain wider appreciation and acceptance for downstream processing assay requirements because commercial instruments have been designed exclusively for standard benchtop laboratory use. Manual sample acquisition, preparation, sample introduction, and data reduction are the rule as is the fact that most HPCE systems must be operated by HPCE specialists. These instruments have remained exclusively in the province of remote laboratories operating in support of downstream operations and these instruments do not promote the advantages of PAT technology in downstream operations.

New Downstream Technology

We are introducing an on-line and at-line process analysis technology specific for protein identification and quantitation in a downstream process application. This instrument9 fully automates the entire process and is purposely built for on-line assays for protein identity and titer as envisioned by the FDA PAT initiative. The instrument incorporates and can be used on-line with an automatic, sanitary sample port interface, or can be used at-line with samples introduced by the instrument's autosampler. In either case, the entire sample introduction, preparation, separation, detection, and data reduction are performed automatically by the instrument without operator input. Once the sample is introduced to the instrument it is transferred directly to the sample preparation module, which delivers an appropriately prepared sample to a HPCE module that automatically performs the separation. Detection is performed by an ultraviolet absorbance detector. Data reduction and reporting are performed by a data system based on standard HPLC data and user interfaces. The concentration dynamic range of the instrument is from ?g/mL to g/mL due to the internal automatic dilution-concentration system component of the sample preparation module. Molecular weight range for the instrument is 10 to 200 kD. Calibration of the instrument is through a timed, automatic introduction of calibration standards in a manner typical of calibration for similar HPLC systems. Cycle times are consistent with the needs for most downstream processing.


Quick Recap
Biotechnology manufacturing, particularly downstream processes, has many operations and opportunities suited to the premise of the PAT initiative—namely, improving production efficiency, yield, and product quality. Several technologies have been implemented in downstream processing for the purpose of on-line assays that have proven the concept. New, versatile instrumentation technologies for downstream process applications will continue to emerge as the PAT initiative becomes more fully implemented in biotechnology and biological manufacturing.

George Barringer, PhD, is president and CSO of Groton Biosystems, 85 Swanson Road, Boxborough, MA 01719, 987.266.9222, fax 978.266.9223

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here